Alex Karlsson- Parra

Alex Karlsson- Parra

Company: Immunicum

Job title: CSO


Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration 3:30 pm

Proposed mode of action Preclinical in vivo data in combination with anti-VEGF antibodies and checkpoint inhibitors Clinical data from a randomized phase 2 study in mRCC in combination with sunitinib (VEGFR-TKI) leading to Regenerative Medicine Advanced Therapy Designation by FDARead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.